Loading clinical trials...

Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms | Clinical Trials | Clareo Health

RECRUITING

Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms

Immuno-Positron Emission Tomography, Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms

NCT06305728•Memorial Sloan Kettering Cancer Center

View on ClinicalTrials.gov

Summary

The purpose of this study is for researchers to find ways of detecting pancreatic ductal adenocarcinoma/PDAC early to avoid the invasive procedure of surgery. The study researchers think a combination of imaging and a series of blood tests may be an effective way to detect PDAC early. In this study, researchers will look at whether a combination of the following types of imaging with blood tests can detect PDAC in pancreatic cysts: * The ImmunoPET scan (immune-positron emission tomography scan) with the imaging agent 89Zr-DFO-HuMab-5B1 * The HP MRI scan (hyperpolarized pyruvate magnetic resonance imaging scan)

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Men and women aged \>18 years
•Pancreatic cystic neoplasm deemed to be high risk and requiring surgical resection
•Able to provide informed consent

Exclusion Criteria

•Pathologic evidence of pancreatic cancer
•Pregnant or breast-feeding patients
•Refusal or inability to tolerate scan (eg anxiety or claustrophobia)
•Inability to lay flat or meet the standard requirements of traditional MRI
•Hepatic function from assays obtained within 6 weeks prior to the study enrollment. For each patient, the upper limit of normal (ULN) value for a particular assay will be defined by the normal reference values of the laboratory that performed the assay
•1. Bilirubin \> 1.5 x ULN
•2. AST/ALT \> 2.5 x ULN
•3. Albumin \< 3 g/dL
•4. GGT \> 2.5 x ULN if Alkaline Phosphatase \> 2.5 x ULN
•Renal function with Creatinine \> 1.5 x ULN or creatinine clearance \< 60 mL/min, from assays obtained within 6 weeks prior to study enrollment
+1 more criteria

Locations (8)

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth (Limited protocol activities)

Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen (Limited Protocol Activities)

Montvale, New Jersey, United States

Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity)

Commack, New York, United States

Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, United States

Memorial Sloan Kettering Cancer Center (All protocol activites)

New York, New York, United States

Weill Cornell Medical Center (Specimen Analysis Only)

New York, New York, United States

Memorial Sloan Kettering Nassau (Limited Protocol Activites)

Rockville Centre, New York, United States

Key Dates

Start Date

March 4, 2024

Primary Completion Date

March 4, 2030

Completion Date

March 4, 2030

Last Updated

October 9, 2025

Enrollment

ESTIMATED participants

Conditions

Pancreatic Cyst

Interventions

89Zr-DFO-HuMab-5B1 immunoPET

DIAGNOSTIC_TEST

HP MRI

DIAGNOSTIC_TEST

Blood assay

COMBINATION_PRODUCT

Contacts

Kevin Soares, MD

CONTACT

212-639-3195 soaresk@mskcc.org

David Kelson, MD

CONTACT

646-888-4179 kelsend@MSKCC.ORG

Determination of Pancreatic Steatosis Prevalence and Correlation With High-risk Cyst Features

NCT05334836

Pancreatic SteatosisPancreatic Cyst

View study

RECRUITING

Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)

NCT04743479

Pancreatic CancerDiabetes+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 9, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms

Inclusion Criteria

Exclusion Criteria

Determination of Pancreatic Steatosis Prevalence and Correlation With High-risk Cyst Features

Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)

The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)

The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

Early Detection of Pancreatic Cystic Neoplasms

EUS-guided Ablation of Pancreatic Cyst Neoplasms